T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
226
Zscaler
ZS
$28.7B
| $579M | 0.06% |
2,572,358
+777,414
| +43% | +$219M |
|
227
Guardant Health
GH
$22.2B
| $576M | 0.06% |
5,636,078
+1,414,441
| +34% | +$127M |
|
228
Adobe
ADBE
$103B
| $573M | 0.06% |
1,636,790
+257,597
| +19% | +$87.6M |
|
229
PG&E
PCG
$38.3B
| $571M | 0.06% |
35,555,307
-1,388,995
| -4% | -$22.2M |
|
230
Rockwell Automation
ROK
$50.1B
| $571M | 0.06% |
1,468,132
-1,755,056
| -54% | -$660M |
|
231
Blackrock
BLK
$180B
| $567M | 0.06% |
529,706
+4,514
| +0.9% | +$4.93M |
|
232
PepsiCo
PEP
$189B
| $564M | 0.06% |
3,928,303
-98,102
| -2% | -$14.4M |
|
233
KKR & Co
KKR
$99.5B
| $561M | 0.06% |
4,401,951
+1,295,099
| +42% | +$161M |
|
234
SiteOne Landscape Supply
SITE
$4.22B
| $556M | 0.06% |
4,466,791
-183,228
| -4% | -$23.2M |
|
235
Medtronic
MDT
$116B
| $555M | 0.06% |
5,777,317
-146,360
| -2% | -$14.2M |
|
236
Tower Semiconductor
TSEM
$29.4B
| $550M | 0.06% |
4,682,152
+4,541,235
| +3,223% | +$437M |
|
237
Credo Technology Group
CRDO
$50B
| $548M | 0.06% |
3,811,596
-1,539,094
| -29% | -$237M |
|
238
Alliant Energy
LNT
$18.2B
| $546M | 0.06% |
8,393,496
+7,460,117
| +799% | +$500M |
|
239
Phillips 66
PSX
$90B
| $545M | 0.06% |
4,224,814
-1,225,109
| -22% | -$165M |
|
240
Popular Inc
BPOP
$11.2B
| $543M | 0.06% |
4,361,681
+58,452
| +1% | +$6.91M |
|
241
Travelers Companies
TRV
$77.2B
| $543M | 0.06% |
1,871,059
-3,871,680
| -67% | -$1.09B |
|
242
Hubbell
HUBB
$27.1B
| $539M | 0.06% |
1,214,236
+60,071
| +5% | +$26.3M |
|
243
CF Industries
CF
$18.2B
| $535M | 0.06% |
6,922,036
-42,403
| -0.6% | -$3.48M |
|
244
AGCO
AGCO
$7.11B
| $535M | 0.06% |
5,131,776
-56,592
| -1% | -$6.02M |
|
245
VICI Properties
VICI
$28.7B
| $534M | 0.06% |
19,005,214
-1,346,982
| -7% | -$40M |
|
246
RenaissanceRe
RNR
$13.2B
| $532M | 0.06% |
1,891,032
-980,904
| -34% | -$258M |
|
247
Baker Hughes
BKR
$63.8B
| $530M | 0.06% |
11,635,780
+4,278,573
| +58% | +$203M |
|
248
Ryanair
RYAAY
$30.8B
| $527M | 0.06% |
7,304,889
+985,939
| +16% | +$64.1M |
|
249
PTC
PTC
$16.1B
| $527M | 0.06% |
3,025,046
+41,240
| +1% | +$7.66M |
|
250
Apollo Global Management
APO
$81.9B
| $519M | 0.06% |
3,585,283
-2,313,437
| -39% | -$307M |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.